Shares & Derivatives
Biolidics: Overhyped or multi-bagger gem?
By New Academy of Finance  •  April 26, 2020
Biolidics limited, a Singapore-based medical technology company has been hogging the limelight recently after inking a US distribution deal for its Covid-19 test kits. Its shares have been on a roller coaster ride, reaching as high as S$0.84 on 22 April before dropping back to the current level of S$0.45 after the disclosure of its US distribution partner. Is the fuss over the stock hugely overhyped or is this a multi-bagger gem in the making? I thought it will be interesting to do a little “sleuthing” of the company to see if it is worth an investment. Do note that this article is purely an opinion piece and not one construed to recommend a sell or buy off the counter. I believe the investment thesis of Biolidics rests on its foray into the US market for its COVID-19 rapid test kit. However, before that, a summary of what happened in...
Read the full article
By New Academy of Finance
I have got no sob-stories to entertain ya. I am just a regular joe, happily married, with two “highly energetic” young boys that can never seem to settle down! Life is peaceful, or if you wish to put it with a tad of negative connotation to it, BORING. Some say boring is good!
LEAVE A COMMENT
LEAVE A COMMENT

Your email address will not be published.

*

Your Email Address will not be published
*

1 Comments

One response to “Biolidics: Overhyped or multi-bagger gem?”

  1. Dave says:

    Why would they sign an exclusivity deal at such tiny volumes? Who is getting fired for that mess?

Leave a Reply

Your email address will not be published.

Read More Articles
More from thefinance
%d bloggers like this: